InvestorsHub Logo
Followers 138
Posts 23698
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Wednesday, 04/25/2018 10:04:47 PM

Wednesday, April 25, 2018 10:04:47 PM

Post# of 469763
Anavex 2-73 and/or Anavex 3-71 as a potential treatment for Wolfram Syndrome

Wolfram syndrome: MAMs' connection?
Delprat B1,2, Maurice T3,4, Delettre C5,6.
Author information
Abstract
Wolfram syndrome (WS) is a rare neurodegenerative disease, the main pathological hallmarks of which associate with diabetes, optic atrophy, and deafness. Other symptoms may be identified in some but not all patients. Prognosis is poor, with death occurring around 35 years of age. To date, no treatment is available. WS was first described as a mitochondriopathy. However, the localization of the protein on the endoplasmic reticulum (ER) membrane challenged this hypothesis. ER contacts mitochondria to ensure effective Ca2+ transfer, lipids transfer, and apoptosis within stabilized and functionalized microdomains, termed "mitochondria-associated ER membranes" (MAMs). Two types of WS are characterized so far and Wolfram syndrome type 2 is due to mutation in CISD2, a protein mostly expressed in MAMs. The aim of the present review is to collect evidences showing that WS is indeed a mitochondriopathy, with established MAM dysfunction, and thus share commonalities with several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as metabolic diseases, such as diabetes.



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840383/

Good luck and GOD bless,

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News